共 50 条
- [41] Updated results of a randomized phase II trial for neoadjuvant versus adjuvant docetaxel/cisplatin chemotherapy in patients with locally advanced gastric cancer.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)Kim, Young WooRyu, Keun WonChoi, Il JuKook, Myeong-CherlPark, Young IeeKim, Hark K.
- [42] Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)McArthur, Heather L.Leal, JorgeShiao, Stephen LawrenceCarter, MeredithBasho, Reva K.Phillips, MichelleChan, DavidHool, HugoPark, Dorothy J.El-Masry, MaryMcAndrew, PhilomenaSikaria, SwatiSpring, LauraBardia, AdityaTighiouart, MouradDadmanesh, FarnazGiuliano, Armando E.Sanchez, KatherinePage, David B.
- [43] Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Zhang, TianStaats, Janet S.Chan, CliburnHarrison, Michael RogerO'Donnell, Peter H.Batich, Kristen A.Chen, TianlingKrejsa, CecileIzumi, RaquelGeorge, Daniel J.Weinhold, Kent J.
- [44] Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma.CANCER RESEARCH, 2021, 81 (13)Piperno-Neumann, SophieHassel, Jessica C.Rutkowski, PiotrBaurain, Jean-FrancoisButler, Marcus O.Schlaak, MaxSullivan, Ryan J.Ochsenreither, SebastianDummer, ReinhardKirkwood, John M.Joshua, Anthony M.Sacco, Joseph J.Shoushtari, Alexander N.Orloff, MarlanaCarvajal, Richard D.Hamid, OmidAbdullah, Shaad E.Holland, ChrisGoodall, HowardNathan, Paul
- [45] Immunologic and clinical outcomes of a Randomized phase II trial of two multipeptide Vaccines for melanoma in the adjuvant settingCLINICAL CANCER RESEARCH, 2007, 13 (21) : 6386 - 6395Slingluff, Craig L., Jr.Petroni, Gina R.Chianese-Bullock, Kimberly A.Smolkin, Mark E.Hibbitts, SarahMurphy, CherylJohansen, NaomiGrosh, William W.Yamshchikov, Galina V.Neese, Patrice Y.Patterson, James W.Fink, RobynRehm, Patrice K.
- [46] The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Lucas, Minke W.Lijnsvelt, JudithPulleman, SaskiaScolyer, Richard A.Menzies, Alexander M.Van Akkooi, Alexander Christopher JonathanVan Houdt, Winan J.Shannon, Kerwin FrankPennington, ThomasSuijkerbuijk, KarijnKapiteijn, EllenVan der Veldt, Astrid Aplonia MariaCarlino, Matteo S.Sandhu, ShahneenGonzalez, MariaKlop, Charlotte L. Zuur W. Martin. C.Long, Georgina V.Blank, Christian U.
- [47] KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Long, Georgina V.Eggermont, Alexander M.Gershenwald, Jeffrey E.Schadendorf, DirkAscierto, Paolo AntonioDummer, ReinhardHauschild, AxelCarlino, Matteo S.Ribas, AntoniRobert, CarolineScolyer, Richard A.Sondak, Vernon K.Cohen, Jonathan E.Zhang, JinchunGrebennik, Dmitri O.Krepler, ClemensLuke, Jason J.
- [48] Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally for Advanced Head and Neck Squamous Cell CarcinomaCLINICAL CANCER RESEARCH, 2022, 28 (07) : 1345 - 1352Wise-Draper, Trisha M.Gulati, ShuchiPalackdharry, SarahHinrichs, Benjamin H.Worden, Francis P.Old, Matthew O.Dunlap, Neal E.Kaczmar, John M.Patil, YashRiaz, Muhammed KashifTang, AliceMark, JonathanZender, ChadGillenwater, Ann M.Bell, DianaKurtzweil, NickyMathews, MariaAllen, Casey L.Mierzwa, Michelle L.Casper, KeithJandarov, RomanMedvedovic, MarioLee, J. JackHarun, NusratTakiar, VinitaGillison, Maura
- [49] Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialCLINICAL CANCER RESEARCH, 2020, 26 (19) : 5140 - 5152Uppaluri, RavindraCampbell, Katie M.Egloff, Ann MarieZolkind, PaulSkidmore, Zachary L.Nussenbaum, BrianPaniello, Randal C.Rich, Jason T.Jackson, RyanPipkorn, PatrikMichel, Loren S.Ley, JessicaOppelt, PeterDunn, Gavin P.Barnell, Erica K.Spies, Nicholas C.Lin, TianxiangLi, TiantianMulder, David T.Hanna, YoustinaCirlan, IuliaPugh, Trevor J.Mudianto, TennyRiley, RachelZhou, LiyeJo, Vickie Y.Stachler, Matthew D.Hanna, Glenn J.Kass, JasonHaddad, RobertSchoenfeld, Jonathan D.Gjini, EvisaLako, AnaThorstad, WadeGay, Hiram A.Daly, MackenzieRodig, Scott J.Hagemann, Ian S.Kallogjeri, DorinaPiccirillo, Jay F.Chernock, Rebecca D.Griffith, MalachiGriffith, Obi L.Adkins, Douglas R.
- [50] IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATCJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Cabanillas, Maria E.Gunn, Gary BrandonZafereo, Mark E.Wang, Rui JenniferIyer, Priyanka C.Maniakas, AnastasiosSpiotto, Michael T.Dadu, Ramona